These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32805167)

  • 21. Antithrombotic treatment in peripheral artery disease.
    Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
    Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
    Burgos KD; Sienko SE; Hoffman JL; Koerber JM; Smythe MA
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):372-378. PubMed ID: 28301906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
    Kruger PC; Guzik TJ; Eikelboom JW
    Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotics in stable peripheral artery disease.
    Kaplovitch E; Rannelli L; Anand SS
    Vasc Med; 2019 Apr; 24(2):132-140. PubMed ID: 30799766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
    Bauersachs R; Zannad F
    Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 28. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era.
    Kaplovitch E; Anand SS
    Cardiovasc Res; 2019 Oct; 115(12):e121-e124. PubMed ID: 31321405
    [No Abstract]   [Full Text] [Related]  

  • 29. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Camm AJ
    Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of rivaroxaban in the prevention of atherosclerotic events.
    Sanmartín M; Bellmunt S; Cosín-Sales J; García-Moll X; Riera-Mestre A; Almendro-Delia M; Hernández JL; Lozano F; Mazón P; Suarez Fernández C
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):771-780. PubMed ID: 31269825
    [No Abstract]   [Full Text] [Related]  

  • 31. Rivaroxaban (Xarelto) - a new peripheral artery disease indication.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):172-173. PubMed ID: 35085206
    [No Abstract]   [Full Text] [Related]  

  • 32. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
    Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S;
    N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Yuan J
    BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk?
    Zhang J; Vallabhaneni SR; Lip GYH
    Eur Heart J; 2021 Oct; 42(39):4049-4052. PubMed ID: 34477839
    [No Abstract]   [Full Text] [Related]  

  • 35. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological management of obstructive peripheral arterial disease: two case reports.
    Détriché G; Lanéelle D; Radureau C
    Hosp Pract (1995); 2021 Dec; 49(5):379-383. PubMed ID: 34278930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.
    Kirchhof P; Haas S; Amarenco P; Hess S; Lambelet M; van Eickels M; Turpie AGG; Camm AJ;
    J Am Heart Assoc; 2020 Mar; 9(5):e009530. PubMed ID: 32079476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
    Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A
    Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    De Backer O; Dangas GD; Jilaihawi H; Leipsic JA; Terkelsen CJ; Makkar R; Kini AS; Veien KT; Abdel-Wahab M; Kim WK; Balan P; Van Mieghem N; Mathiassen ON; Jeger RV; Arnold M; Mehran R; Guimarães AHC; Nørgaard BL; Kofoed KF; Blanke P; Windecker S; Søndergaard L;
    N Engl J Med; 2020 Jan; 382(2):130-139. PubMed ID: 31733182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
    Fox KAA; Eikelboom JW; Anand SS; Bhatt DL; Bosch J; Connolly SJ; Harrington RA; Steg PG; Yusuf S
    Eur Heart J; 2019 May; 40(18):1466-1471. PubMed ID: 29945212
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.